Date: 2016-08-10
Type of information: IPO
Company: Epigenomics (Germany - USA)
Investors:
Amount:
Funding type: IPO
Planned used:
Others: * On August 10, 2016, Epigenomics announced that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission (SEC) for a potential U.S. public offering of American Depositary Shares (ADSs) on the NASDAQ stock market. All ADSs to be sold in the offering will be offered by Epigenomics AG. It has not been determined whether or when an offering will be commenced nor have the number of ADSs or the price range for the offering been determined.
Therapeutic area: Cancer - Oncology - Diagnostic
